Navigation Links
ALS Therapy Development Institute and Anida Pharma Partner to Investigate Potential Treatments for ALS

CAMBRIDGE, Mass., Sept. 10, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into a research partnership with Anida Pharma, Inc., to investigate a potential treatment for ALS, also known as Lou Gehrig's disease.   


Under the terms of the agreement with Anida, ALS TDI will test their lead compound, Neuroprotectin D1 (NPD1), in SOD1 mice for functional benefit.  NPD1, also referred to as Protectin D1 (PD1), activates resolution circuits to control neuroinflammation and prevent cell death, but also has trophic effects. To date, ALS TDI has conducted preclinical proof of concept studies with NPD1 in SOD1 mice. Through these pharmacodynamic studies, ALS TDI has demonstrated that it can deliver pharmacologically active levels of NPD1 to the central nervous system of the SOD1 mice, providing sufficient evidence to move it forward for additional preclinical testing.

"This partnership is yet another example of how our Institute, which is quite literally led by ALS patients and their families, identifies opportunities that otherwise may not get evaluated as a potential treatment for ALS," says Steve Perrin, Ph.D., CEO and CSO of ALS TDI. "It really is about moving as quickly as possible for patients today, and we are committed to doing just that through this partnership with Anida and the more than two dozen other programs our experienced drug development team is simultaneously working on at the Institute."

Anida marks the 12th venture philanthropy investment ALS TDI has made. Since 2007, ALS TDI has made more than $5 million of venture philanthropy investments in small biotechs like Anida Pharma. Previous venture philanthropy investments have been made with to-BBB, Neurotune, Regenesance, Glialogix, Aestus and others under confidential agreements.

"The possibility to partner with ALS TDI as a world-leading institute for ALS research is an extraordinary opportunity for Anida to accelerate its ALS drug development program towards the clinic. We believe that based on its unique property of multiple actions: regulating inflammation and cell death, but also exerting neurotrophic effects, NPD1 offers an exciting potential for the treatment of ALS," says Per Gjorstrup, M.D., Ph.D., President and CEO of Anida Pharma. 

About ALS
Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is a progressive neurodegenerative disease that leads to paralysis, due to the death of motor neurons in the spinal cord and brain. There is no known cure for the disease. About 5,000 people in the US are diagnosed with ALS each year; the incidence is similar to multiple sclerosis. However, with no effective treatment, the average patient survives only two to five years following diagnosis. There are about 30,000 people in the US diagnosed with ALS today. The worldwide population of ALS patients is estimated at 450,000.

About ALS Therapy Development Institute (ALS TDI)
The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) as soon as possible for patients today. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust target discovery program, while simultaneously operating the world's largest efforts to preclinically determine the efficacy of potential therapeutics, including a pipeline of dozens of small molecules, protein biologics, gene therapies and cell-based constructs. The world's first nonprofit biotech institute, ALS TDI employs 30 professional scientists, evaluates dozens of potential therapeutics each year and is currently executing a Phase IIA clinical trial of TDI-132 (Novartis' Gilenya®) in ALS patients.  Built by and for patients, the Cambridge, Massachusetts-based research institute collaborates with leaders in both academia and industry to accelerate ALS therapeutic development, including Biogen Idec, UCB, the Gladstone Institutes, MDA and RGK Foundation. For more information, please visit us online at

About Anida Pharma
Anida Pharma, Inc. is a biopharmaceutical company developing novel first-in-class therapies to treat amyotrophic lateral sclerosis (ALS; Lou Gehrig disease), Parkinson's disease, other central nervous system disorders, and hearing loss. Our therapeutic concept is based on activating the body's own homeostatic mechanisms to regulate inflammation, prevent cell death and stimulate tissue repair. Visit our website: to learn more.

Media Contacts:
Mari Sullivan, ALS TDI, 617-441-7220,
Per Gjorstrup, Anida Pharma, 617-331-5033,

SOURCE ALS Therapy Development Institute
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
3. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
6. Aperture Health, Inc. focuses in on IV Therapy Value Creation and the Merger and Acquisition Activities in the Home Infusion Therapy Sector.
7. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
8. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
9. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
10. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
11. The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease
Post Your Comments:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):